Gilead Sciences June 15th Short Interest Update

Gilead Sciences (NASDAQ:GILD) encountered a drop of 5.8% or -1,529,851 shares in the short positions. The number dropped from 26,229,746 on May 31,2016 to 24,699,895 on June 15,2016. The final interest is 1.9% of the floated stock. The days to cover figure of 3 can be arrived using the average daily exchange of 7,753,315 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Gilead Sciences (NASDAQ:GILD): The stock opened at $81.17 on Friday but the bulls could not build on the opening and the stock topped out at $82.25 for the day. The stock traded down to $80.22 during the day, due to lack of any buying support eventually closed down at $80.47 with a loss of -3.48% for the day. The stock had closed at $83.37 on the previous day. The total traded volume was 12,438,024 shares.

The company shares have dropped -30.30% from its 1 Year high price. On Aug 4, 2015, the shares registered one year high at $120.37 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $84.40 and the 200 Day Moving Average price is recorded at $91.25.

Gilead Sciences (NASDAQ:GILD) has tumbled 2.64% during the past week and has dropped 6.23% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.02%. Gilead Sciences (NASDAQ:GILD) has underperformed the index by 3.4% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.